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Despite initial dramatic response, epidermal growth factor receptor (EGFR) mutant lung 
cancer patients always acquire resistance to EGFR-tyrosine kinase inhibitors (TKIs). 
Gatekeeper T790M mutation in EGFR is the most prevalent genetic alteration 
underlying acquired resistance to EGFR-tyrosine kinase inhibitor (TKI), and EGFR 
mutant lung cancer cells are reported to be addictive to EGFR/Akt signaling even after 
acquired T790M mutation.  
Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein of 
PI3K/PDK1/Akt that determines receptor signal selectivity for non-mutated EGFR, and 
assessed its role in EGFR mutant lung cancer with or without gatekeeper T790M 
mutation. Cell line based assays showed that Aki1 constitutively associates with mutant 
EGFR in lung cancer cells with (H1975) or without (PC-9 and HCC827) T790M 
gatekeeper mutation. Silencing of Aki1 induced apoptosis of EGFR mutant lung cancer 
cells. Treatment with Aki1 siRNA dramatically inhibited growth of H1975 cells in a 
xenograft model. Moreover, silencing of Aki1 further potentiated growth inhibitory effect 
of new generation EGFR-TKIs against H1975 cells in vitro. Aki1 was frequently 
expressed in tumor cells of EGFR mutant lung cancer patients (53/56 cases), including 
those with acquired resistance to EGFR-TKI treatment (7/7 cases). Our data suggest 
4 
 
that Aki1 may be a critical mediator of survival signaling from mutant EGFR to Akt, and 
may therefore be an ideal target for EGFR mutant lung cancer patients, especially those 
with acquired EGFR-TKI resistance due to EGFR T790M gatekeeper mutation. 
 





Lung cancer with epidermal growth factor receptor (EGFR) activating mutations, 
such as exon 19 deletion and exon 21 L858R point mutation, responds to the 
EGFR-tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib (1). Recent clinical 
trials demonstrated much longer progression-free survival for EGFR mutant lung cancer 
patients when treated with gefitinib compared to conventional chemotherapy (2,3). 
However, almost without exception, the responders relapse after various times due to 
acquiring resistance to EGFR-TKIs (1,4). 
 The development of gatekeeper mutations, such as T315I in Abl (5), D473H in 
SMO (6), and L1196M in ALK (7), is the most common mechanism of acquired tyrosine 
kinase inhibitor resistance (8). In cases of EGFR mutant lung cancer, EGFR T790M 
mutation is detected in about 50% of patients with acquired resistance to EGFR-TKIs 
(4,8,9). T790M mutation results in increased EGFR affinity to ATP, reducing binding of 
EGFR-TKIs, and thus inducing resistance (10). However, EGFR mutant lung cancer 
cells with T790M mutation are still dependent on EGFR-mediated signaling (10), and 
therefore further elucidation of mutant EGFR-mediated signaling may facilitate the 
development of novel effective therapeutic strategies against lung cancer with EGFR 
mutations, including T790M gatekeeper mutation. 
New generation EGFR-TKIs, such as irreversible EGFR-TKIs and mutant 
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EGFR selective TKIs, were expected to overcome acquired resistance caused by 
T790M secondary mutation (11–15). However, several irreversible EGFR-TKIs failed to 
meet primary endpoints in clinical trials in EGFR-TKI-refractory lung cancer and induced 
severe adverse effects, such as diarrhea, skin rush/acne, stomatitis, and nail effect 
(1,16). More recently, a phase Ib trial of EGFR dual inhibition with irreversible EGFR-TKI 
afatinib plus anti-EGFR monoclonal antibody cetuximab indicated with a 40% objective 
response rate in 47 patients with EGFR-TKI acquired resistance (17), suggesting that 
many tumors are still addicted to the EGFR signaling pathway, including EGFR T790M 
gatekeeper mutation in clinical trials. Therefore, new intensification treatment targeting 
EGFR signaling is expected to get for more clinical benefit, whiles, the feasibility of 
these strategies should be evaluated carefully in clinical trials. 
 Receptor tyrosine kinases, such as EGFR, PDGFRs, and VEGFRs, utilize 
several common downstream signaling pathways, including MAPK/ERK and PI3K/Akt, 
while each receptor shows different or specific biological activity after ligand stimulation. 
Scaffold proteins that can simultaneously interact with two or more protein binding 
partners are thought to ensure specificity as well as temporal regulation of signal 
transduction. Thus, scaffold proteins may be important targets for regulating 
receptor-mediated signaling. There is accumulating evidence that Akt signaling is 
7 
 
essential for mediating survival signals in EGFR mutant lung cancer cells (18,19). While 
several molecules, including KSP (20), Paxillin (21), RKIP (22), and JIP-1 (23), are 
known to act as scaffolds for MAPK-ERK (24), scaffold proteins for Akt have not been 
well documented. Recently, we reported Akt kinase-interacting protein1 (Aki1) as the 
first identified scaffold in the phosphoinositide 3-kinase 
(PI3K)/3-phosphoinositide-dependent protein kinase 1(PDK1)/Akt pathway. Aki1 
selectively forms a complex with EGFR and Akt in response to EGF stimulation, 
mediates Akt activation by PDK1, and hence contributes to cell survival and proliferation 
(25). However, Aki1, the scaffold proteins for therapeutic target in cancers, have yet to 
be identified. 
In the present study, we examined whether Aki1 would act as a determinant of 
receptor signaling selectivity of mutant EGFR and could be a therapeutic target for 
EGFR mutant lung cancer, including that with T790M gatekeeper mutation. 
 
Results 
High levels of Aki1 protein expression in EGFR mutant lung cancer cell lines 
As the first step to assess the involvement of Aki1 in EGFR mediating signal of 
lung cancer cells, we examined the expression of Aki1 protein and its associated 
proteins (PDK1, Akt, and EGFR) in 5 human lung adenocarcinoma cells with or without 
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EGFR mutations, comparing that in 2 human lung embryonic fibroblast cell lines, by 
Western blotting (Fig. 1A). All of the cell lines examined expressed Aki1 and PDK1 
protein at various levels. The levels of Aki1 tend to be higher in EGFR mutant lung 
cancer cell lines than in lung fibroblast cell lines. 
 EGFR was also detected in all lung cancer and fibroblast cell lines at various 
levels. Interestingly, phosphorylated EGFR was detected in EGFR mutant lung cancer 
cell lines, but not detected in EGFR wild type lung cancer cell lines and fibroblast cell 
lines. The co-detection of Aki1 and phosphorylated EGFR in these cell lines suggested 
interactions between Aki1 and mutant EGFR because Aki1 was shown to bind 
preferentially to activated wild-type EGFR (25). 
Aki1 constitutively associates with EGFR without ligand stimulation in EGFR 
mutant lung cancer cells 
To determine the role of Aki1 in the EGFR/PDK1/Akt pathway, we examined the 
association between Aki1 and EGFR by immunoprecipitation. Aki1 constitutively 
associated with EGFR in all three EGFR mutant lung cancer cell lines (Fig. 1B). 
Consistent with the results of previous studies (25), Aki1 did not associate with IGF-1R, 
irrespective of IGF-1 stimulation, indicating selective binding of Aki1 to EGFR (Fig. 1B). 
Moreover, treatment with EGFR-TKI didn’t affect the association between Aki1 and 
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EGFR/PDK1/Akt (Fig. S1). These results further suggest that Aki1 may be involved 
deeply in signal transduction through mutant EGFR. 
Specific downregulation of Aki1 inhibits cell viability and induces cell apoptosis 
in EGFR mutant lung cancer cells 
To determine the role of Aki1 in EGFR mutant lung cancer cell lines, we used 
specific small interfering RNA (siRNA) for Aki1 knockdown. Treatment with Aki1-specific 
siRNA suppressed Aki1 protein expression, and more decreased the viability of EGFR 
mutant cells (PC-9, HCC827, and H1975) than EGFR wild type cells (A549, PC14PE6) 
(Fig. 2A, S2). To confirm the specificity of the Aki1 siRNA used, we constructed RNA 
interference (RNAi)-resistant Aki1 cDNA by mutating the sequence targeted by Aki1 
siRNA without changing the amino acid sequence. Transfection of wild-type Aki1 or 
RNAi-resistant Aki1 resulted in increased expression of Aki1 protein in PC-9 cells (Fig. 
S3A). Treatment with Aki1 siRNA attenuated Aki1 protein expression and cell viability in 
parental and even in wild-type Aki1-transfected cells (Fig. S3B,C). However, Aki1 
siRNA did not downregulate exogenous Aki1 in RNAi-resistant Aki1 cDNA-transfected 
cells. Transfection of RNAi-resistant Aki1 cDNA overcame the Aki1 siRNA-mediated 
decrease in cell viability (Fig. S3C), indicating the specificity of siRNA to Aki1. On the 
other hand, the effects of Aki siRNA in lung fibroblasts, MRC-5 and IMR-90, were only 
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marginal (Fig. 2A), suggesting that Aki knockdown selectively inhibits viability of cancer 
cells with dependent EGFR signal, especially in EGFR mutant lung cancer cells. In 
addition, to rule out any bystander effect of the siRNA, we performed cell culture using 
two color labeling. We found that Aki1-1 siRNA did not show any discernible bystander 
effect. Therefore, we conclude that the bystander effect is not the primary mechanism 
by which the Aki1-1siRNA treatment inhibited tumor cell growth, under our experimental 
conditions (Fig. S5A, S5B). Therefore, we focused solely on EGFR mutant lung cancer 
cells. Western blotting analyses indicated that Aki1 knockdown reduced 
phosphorylation of downstream molecules, Akt and S6, and increased the levels of the 
proapoptotic molecule, cleaved PARP (Fig. 2B), consistent with the decrease in cell 
viability. Furthermore, we also found that knockdown of Aki1 discernibly induced 
apoptosis in PC-9, HCC827, and H1975 cells (Fig. 2C). 
We next assessed the effect of Aki1 inhibition, in comparison with EGFR 
inhibition, in EGFR mutant lung cancer cell lines. Like EGFR knockdown and erlotinib, 
Aki1 knockdown considerably inhibited viability of PC-9 and HCC827 cells with exon 19 
deletion in EGFR. In addition, Aki1 knockdown inhibited viability of H1975 cells with 
exon 21 L858R and exon 20 T790M double mutations as potently as EGFR siRNA, 
while erlotinib had no effect (Fig. 3A,B). These results suggest that targeting of Aki1 
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may be valuable for treating EGFR mutant lung cancer cells, especially with T790M 
gatekeeper mutation. 
Aki1 knockdown inhibits tumor growth of lung cancer with EGFR T790M 
secondary mutation in vivo 
Next, we examined the antitumor potential of Aki1 siRNA against H1975 cells 
with EGFR T790M gatekeeper mutation in vivo. Intratumoral injection of either scramble 
or Aki1 siRNA complexed with Invivofectamine was performed on days 5 and 8. In a 
previous report, MAGE-D1 gene knockdown by three direct injections of siRNA 
complicated with invivofectamine into the local region indicated 50% inhibition of protein 
expression (26). Aki1 siRNA treatment dramatically inhibited tumor growth in 
comparison with control or scramble siRNA (Fig. 4A, B). We confirmed knockdown of 
Aki1 and the inhibition of downstream signaling molecule, S6, in tumors by Western 
blotting (Fig. 4C). These results clearly indicated the therapeutic potential of Aki1 siRNA 
against lung cancer with EGFR T790M mutation in vivo. 
Combined Aki1 and EGFR blockade strongly suppressed cell viability of lung 
cancer cells with EGFR T790M secondary mutation 
Irreversible EGFR-TKIs and mutant selective EGFR-TKIs were developed to 
overcome EGFR T790M gatekeeper mutation-mediated resistance to erlotinib and 
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gefitinib. Here, we examined whether Aki1 knockdown could augment the therapeutic 
efficacy of these new generation EGFR-TKIs. Irreversible EGFR-TKI, CL-387,785, and 
BIBW2992, and the mutant-selective EGFR-TKI, WZ4002, reduced the viability of 
H1975 cells, while erlotinib had no such effect. Aki1 knockdown suppressed cell viability 
and further augmented the various dose inhibitory effects of CL-387,785, BIBW2992, 
and WZ4002 (Fig. 5A, Fig. S4). Consistent with these findings, Aki1 knockdown 
decreased the levels of Akt and S6 phosphorylation, and increased the level of Par-4 
and cleaved PARP, when combined with WZ4002 (Fig. 5B). These results suggest the 
usefulness of Aki1 knockdown combined with new generation EGFR-TKIs against lung 
cancer with EGFR T790M gatekeeper mutation. 
Aki1 is frequently expressed in EGFR mutant lung cancer  
We next examined Aki1 expression in 56 clinical specimens obtained from 56 
lung cancer patients with EGFR mutation (Fig. 6A, Table. S1). To confirm the specificity 
of the Aki1 by immunohistochemical staining, we performed Aki1 antibody absorption 
test by Aki1 peptide. The staining of Aki1 was remarkably diminished by pretreatment of 
sections with an Aki peptide at 4°C overnight, compared with saline treatment, 
indicating the specificity of the antibody which we used for Aki1 staining (Fig. S6). 
Forty-two tumors were obtained from EGFR-TKI naïve patients. Seven tumors were 
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from patients who showed intrinsic resistance to the EGFR-TKIs, gefitinib or erlotinib. 
Another 7 tumors were from patients who showed acquired resistance to EGFR-TKIs 
(Fig. 6A). Of 42 EGFR-TKI naïve tumors, the presence of Aki1 protein was scored as 
2+ in 31 tumors (74%), 1+ in 8 tumors (19%), and – in 3 tumors (7%). Aki1 protein was 
detected diffusely in all of 7 tumors with intrinsic resistance: 2+ in 4 (57%), 1+ in 3 (43%). 
Aki1 protein was detected diffusely in all of 7 tumors with acquired resistance: 2+ in 6 
(86%), 1+ in 1 (14%) (Fig. 6A). Aki1 was detected in all tumors with acquired resistance, 
including 4 tumors with EGFR T790M mutation (Table. S1). These findings suggest 
involvement of Aki1 in EGFR mediating signaling in lung cancer with EGFR mutations, 
including T790M gatekeeper mutation. 
 
Discussion 
The results of the present study indicated that Aki1 constitutively associates 
with mutant EGFR even in the present of EGFR-TKI. Silencing of Aki1 induces 
apoptosis of EGFR mutant lung cancer cells, indicating that Aki1 plays crucial roles in 
survival signal transduction in lung cancer cells with EGFR mutations. In a xenograft 
model, silencing of Aki1 markedly inhibited growth of lung cancer cells with EGFR 
T790M gatekeeper mutation. Furthermore, Aki1 was frequently expressed in tumor cells 
of EGFR mutant lung cancer patients. Notably, it was detected in all tumors with 
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acquired resistance to gefitinib or erlotinib, suggesting that Aki1 is an ideal target for 
EGFR mutant lung cancer, especially in cases with acquired EGFR-TKI resistance due 
to EGFR T790M gatekeeper mutation. 
 Although Aki1 associates with wild-type EGFR when activated by EGF (25), it 
binds constitutively with mutant EGFR (Fig. 1B). Previous studies indicated enhanced 
kinase activity and transformation capabilities of EGFR in the presence of L858R or 
exon 19 deletion mutation (27,28). Crystal structure analysis of the L858R mutant 
EGFR showed that this substitution activates the kinase through disruption of 
autoinhibitory interactions, resulting in receptors with high kinase activity compared with 
wild-type EGFR (10,29,30). Consistent with these observations, mutant EGFR was 
constitutively phosphorylated, while the levels were varied among cell lines used in the 
present study. Taken together, these results indicate that Aki1 binds constitutively with 
mutant EGFR because mutant EGFR is constitutively activated. 
 There is accumulating evidence that scaffold proteins maintain signaling 
specificity and facilitate the activation of pathway components (24,31,32). We showed 
that Aki1 constitutively forms complexes with EGFR, PDK, and Akt in EGFR mutant lung 
cancer cells. As in EGFR non-mutated cancer cells (25), Aki1 did not bind to IGF-1R 
even after stimulation with IGF-1 in EGFR mutant cells, indicating that Aki1 is the 
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determinant of receptor signaling selectivity for EGFR. In a phase II clinical trial, 
anti-IGF-1R antibody improved the response rate of conventional chemotherapy in 
non-small cell lung cancer (33). However, the phase III trial was terminated because of 
a trend toward poorer overall survival in the group with anti-IGF-1R antibody. A 
preliminary report of toxicity from a phase II trial with the anti-IGF-1R antibody 
demonstrated severe adverse events, including hyperglycemia (34). These findings 
indicated difficulty of targeting IGF-1R in cancer. As Aki1 is an EGFR-selective scaffold 
protein, Aki1 inhibition may have advantage over nonselective inhibition of IGF-1R or its 
downstream PI3K/Akt pathway in terms of safety. 
 EGFR-T790M gatekeeper mutation is associated with 50% of cases of 
acquired resistance to EGFR-TKIs in EGFR mutant lung cancer (4,8,9). Recently, 
mutant-selective EGFR-TKIs were developed, which inhibit EGFR with not only 
activating mutations, such as exon 19 in-frame deletion and L858R point mutation, but 
also T790M resistant mutation (35). As the inhibitors were reported to have less activity 
for non-mutated EGFR, they may overcome T790M-mediated resistance and reduce 
adverse events, including skin toxicity. We found not only that Aki1 inhibition further 
augmented the efficacy of mutant EGFR-selective TKI and irreversible EGFR-TKI, but 
also that Aki1 constitutively associated with EGFR regardless of treatment with 
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EGFR-TKI. In addition, Aki1 was detected in all tumors with acquired resistance, 
including tumors with EGFR T790M mutation. Our findings indicated the necessity of 
development of efficient Aki1 inhibitors, and suggested that combined use of Aki1 
inhibitors may increase the therapeutic effects and may reduce adverse events 
concerning EGFR blockade of new generation EGFR-TKIs in EGFR mutant lung 
cancer. 
In conclusion, we demonstrated that Aki1 constitutively associates with EGFR 
with activating mutation as well as T790M gatekeeper mutation, plays important roles as 
a determinant of receptor selective signaling for mutant EGFR, and mediates the 
survival signal to Akt. Our data provide a rationale for targeting Aki1 in EGFR mutant 
lung cancer patients, especially in cases with acquired resistance due to EGFR-T790M 
gatekeeper mutation. We are currently developing a drug delivery system for Aki1 
siRNA and small compounds with Aki1 inhibitory activity. 
 
Materials and Methods 
Cell lines and reagents 
The PC-9 and HCC827 human lung adenocarcinoma cell lines with 
EGFR-activating mutation (deletion in exon 19) were purchased from 
Immuno-Biological Laboratories (Gunma, Japan) and American Type Culture Collection 
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(Manassas, VA), respectively (36). The H1975 human lung adenocarcinoma cell line 
with EGFR-L858R/T790M double mutation (10) was kindly provided by Dr. John D. 
Minna (University of Texas Southwestern Medical Center). The A549 human lung 
adenocarcinoma cell line, which expresses wild type EGFR, was purchased from 
American Type Culture Collection. PC14PE6 human lung adenocarcinoma cell line, 
which expresses wild type EGFR, was kindly provided by Dr. Isaiah. J. Fidler (M.D. 
Anderson Cancer Center, Houston, TX) (37). The human lung embryonic fibroblast 
MRC-5 (P30-35) and IMR-90 (P20-25) cell lines were obtained from RIKEN Cell Bank 
(Ibaraki, Japan). H1975, PC-9, and HCC827 cells were cultured in RPMI 1640, and 
MRC-5 and IMR-90 cells were cultured in DMEM supplemented with 10% fetal bovine 
serum (FBS), penicillin (100 units/mL), and streptomycin (50 μg/mL), in a humidified 
CO2 incubator at 37°C. All experiments were performed in medium supplemented with 
10% FBS. Erlotinib hydrochloride was obtained from Roche Pharma AG (Basel, 
Switzerland). CL-387,785 was purchased from Calbiochem (San Diego, CA). 
BIBW2992 and WZ4002 were purchased from Seleck Chemicals (Houston, TX). 
Human wild-type Aki1 cDNA in the pFLAG-CMV-2 vector was generated previously (25). 
RNAi-resistant Aki1 cDNA in the pFLAG-CMV-2 vector was generated by mutating 




Immunoprecipitation and Western blotting 
Tumor cells were incubated in 10 mL of RPMI 1640 with 10% FBS for 1 h. The 
cells were then washed twice with PBS, harvested in cell lysis buffer (20 mM Tris, pH 
7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 μg/mL leupeptin, and 1 mM 
phenylmethylsulfonyl fluoride), and flash-frozen on dry ice. After allowing the cells to 
thaw, the cell lysates were collected with a rubber scraper, sonicated, and centrifuged at 
14000 × g (4°C for 20 min). The total protein concentration was measured using a 
Pierce BCA Protein Assay Kit (Pierce, Rockford, IL). Aliquots of 400 μg of total proteins 
were immunoprecipitated with the appropriate antibodies. In some experiments, tumor 
cells were incubated in 10 mL of RPMI 1640 with 0.1% FBS in the presence or absence 
of erlotinib (0.3 μM), CL-387,785 (0.3 μM) for 48 h. In other experiments, tumor cells 
were incubated in 10 mL of RPMI 1640 with 0.1% FBS in the presence or absence of 
EGF (50 ng/mL) or IGF-1 (50 ng/mL) for 10 min. In some experiments, tumor cells were 
transfected with RNAi for 24 h incubation and then incubated in 10 mL of RPMI 1640 
with 10% FBS in the presence or absence of WZ4002 (0.1 μM) for 1 h. Immune 
complexes were recovered with Protein G-Sepharose beads (Zymed Laboratories, San 
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Francisco, CA). For Western blotting assay, immunoprecipitates or cell lysates were 
subjected to SDS-PAGE (Bio-Rad, Hercules, CA) and the proteins were then 
transferred onto polyvinylidene difluoride membranes (Bio-Rad). The membranes were 
blocked with Blocking One (Nacalai Tesque, Kyoto, Japan) for 1 h at room temperature, 
and the blots were then incubated at 4°C overnight with anti-phospho-EGFR (Y1068), 
anti-Akt (40D4), anti-phospho-Akt (Thr308), anti-phospho-Akt (Ser473), anti-Par-4, 
anti-cleaved PARP (Asp214), anti-phospho-S6 ribosomal protein (Ser235/236), anti-S6 
ribosomal protein (5G10), anti-phospho-IGF-1R (Tyr1131), DYKDDDDK (FLAG) tag 
antibody, or anti-β-actin (13E5) antibodies (1:1000 dilution; Cell Signaling Technology, 
Danvers, MA), anti-Aki1 (1:1000 dilution; Bethyl Laboratories, Montgomery, TX), 
anti-PDK1 (1:1000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA), and 
anti-human EGFR (1 μg/mL) or anti-human IGF-1R (0.1 μg/mL) antibody (R&D Systems, 
Minneapolis, MN). After washing three times, the membranes were incubated for 1 h at 
room temperature with secondary Ab (horseradish peroxidase-conjugated 
species-specific Ab). Immunoreactive bands were visualized with SuperSignal West 
Dura Extended Duration Substrate Enhanced Chemiluminescent Substrate (Pierce). 
Each experiment was performed at least three times independently. 
RNAi and proliferation assay in vitro 
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Duplexed Stealth RNAi (Invitrogen) against Aki1, EGFR, and Stealth RNAi 
Negative Control Low GC Duplex #3 (Invitrogen) were used for RNAi assay. Briefly, 
aliquots of 1 × 105 cells in 2 mL of antibiotic-free medium were plated on 6-well plates 
and incubated at 37°C for 24 h. The cells were then transfected with siRNA (250 pmol) 
or scramble RNA using Lipofectamine 2000 (5 μL) in accordance with the 
manufacturer’s instructions (Invitrogen). After 24 h, the cells were washed twice with 
PBS. These partial cells were then used for Western blotting and cell apoptosis assay. 
For proliferation assay, the cells were reseeded at 2 × 103 per well in 96-well plates, and 
incubated in antibiotic-containing RPMI 1640 with 10% FBS for 48 h. Otherwise, after 
24 h of incubation, erlotinib (1 μM), CL-387,785 (0.3, 1 μM), BIBW2992 (0.1, 0.3 μM), or 
WZ4002 (0.1, 0.3 μM) was added to each well, and incubation was continued for a 
further 48 h. These cells were then used for proliferation assay, which was measured 
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium (MTT) dye reduction 
method. An aliquot of MTT solution (2 mg/mL; Sigma, St. Louis, MO) was added to each 
well followed by incubation for 2 h at 37°C. The media were removed and the dark blue 
crystals in each well were dissolved in 100 μL of DMSO. Absorbance was measured 
with an MTP-120 microplate reader (Corona Electric, Ibaraki, Japan) at test and 
reference wavelengths of 550 nm and 630 nm, respectively. The percentage of growth 
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is shown relative to untreated controls. 
Aki1 and EGFR knockdown were confirmed by Western blotting analysis. The 
target sequences of siRNAs were as follows: Aki1-1, 
5'-AGGAGCAGTTCAAACTCTGCATCAA-3' (corresponding to nucleotides 2125 – 
2168); Aki1-2, 5'-AACAAAGACAUCCAGAUCGCCAGGG-3'; EGFR, 
5'-CGGAATAGGTATTGGTGAATTTAAA-3' (corresponding to nucleotides 1014 – 1038). 
Each experiment was performed at least in triplicate, and three times independently. 
Cell apoptosis assay 
Cell apoptosis induced by Aki1-1 siRNA, Aki1-2 siRNA, or Scramble siRNA 
was detected with an Annexin V-FITC Apoptosis Detection Kit I (BD Biosciences 
Pharmingen, Heidelberg, Germany) in accordance with the manufacturer’s protocols as 
we described previously (36). The analysis was performed on a FACSCalibur flow 
cytometer with Cell Quest software (Becton Dickinson, Franklin Lakes, NJ). 
Xenograft studies in SCID mice and in vivo RNAi 
Suspensions of H1975 cells (5×106 cells per 100 μL of PBS) were injected 
subcutaneously into the flanks of 5-week-old male SCID mice (Nihon Clea Co., Ltd). 
Tumor size was measured using digital calipers and tumor volume was calculated as 
0.5 × length × (width)2. All animal experiments complied with the Guidelines for the 
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Institute for Experimental Animals, Kanazawa University Advanced Science Research 
Center (approval no. AP-081088). 
After cell inoculation, 50 μg of either scramble or Aki1 siRNA complexed with 
Invivofectamine (Invitrogen) was injected intratumorally on days 5 and 8. Tumors were 
harvested on day 26. siRNA and Invivofectamine complex was prepared in accordance 
with the manufacturer’s instructions (Invitrogen). Aki1 knockdown in tumor tissue was 
confirmed by Western blotting analysis.  
Patients 
A total of 56 tumor specimens with EGFR-activating mutations were obtained 
from 56 lung adenocarcinoma patients with written informed consent at the Kanazawa 
University Hospital (Kanazawa, Japan), Aichi Cancer Center Hospital (Nagoya, Japan), 
Osaka Medical Center (Osaka, Japan), and National Cancer Center Hospital East 
(Chiba, Japan) in studies with Institutional Review Board approval. Of the 56 patients, 
42 were EGFR-TKI naïve, 7 showed intrinsic resistance, and the remaining 7 patients 
showed partial response to initial EGFR-TKI treatment. As intrinsic resistance is not yet 
clearly defined, in the present study we defined intrinsic resistant tumors as follows: 
response to treatment with an EGFR-TKI as defined by either documented stable 
disease or progressive disease (RECIST). Data for specimens from the 7 patients who 
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showed intrinsic resistance were obtained before EGFR-TKI treatment. For the 7 
patients who showed acquired resistance, tumor specimens were available after the 
development of acquired resistance to EGFR-TKI. Tumors with acquired resistance 
were defined as described previously (38). Four of 7 tumors from 7 patients who 
showed acquired resistance had T790M secondary mutation. 
Histology and immunohistochemistry 
Immunohistochemical staining was carried out on formalin-fixed, 
paraffin-embedded tissue sections of lung adenocarcinoma specimens. Sections 4 μm 
thick were deparaffinized in xylene and rehydrated in decreasing concentrations of 
ethanol. After blocking the endogenous peroxidase activity with 3% aqueous H2O2 
solution for 12 min, the sections were treated with 5% normal horse serum. The 
sections were then reacted with primary antibody (1:100 dilution, rabbit polyclonal 
anti-CC2D1A antibody; Sigma-Aldrich Corp, MO) at 4°C overnight. After washing with 
PBS, the sections were treated with biotin-conjugated anti-rabbit IgG (1:200 dilution) for 
30 min at room temperature and allowed to react for 30 min with 
avidin-biotin-peroxidase complex (ABC) using a Vectastain ABC kit (Vector 
Laboratories). The DAB (3,3'-diaminobenzidine tetrahydrochloride) Liquid System 
(DakoCytomation, Glostrup, Denmark) was used to detect immunostaining. Omission of 
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primary antibodies served as negative control. 
Evaluation of immunohistochemical results 
Aki1 immunoreactivity was evaluated as the percentage of cancer cells with 
positive cytoplasmic staining (0, < 5%; 1+, 5% – 50%; 2+, > 50%). Positive cells were 
defined as those with staining intensity that was the same or greater than that of normal 
bronchial epithelium (Fig. 6B). Evaluation was performed independently by two 
investigators (TY, HU) who were blind to individual clinical information about specimens. 
Statistical analysis 
The statistical significance of differences was analyzed by one-way ANOVA 
performed with GraphPad Prism Ver. 4.01 (GraphPad Software, Inc., San Diego, CA). In 
all analyses, P < 0.05 was taken to indicate statistical significance. 
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Aki1 expression and association to EGFR in EGFR mutant human lung cancer cell lines. 
(A) EGFR mutant human lung cancer cell lines (PC-9, HCC827, and H1975), EGFR 
wild-type human lung cancer cell lines (A549 and PC14PE6), and human lung fibroblast 
cell lines (MRC-5 and IMR-90), were lysed and the indicated proteins were detected by 
Western blotting. (B) EGFR mutant lung cancer cell lines were treated with or without 
EGF (50 ng/mL) or IGF-1 (50 ng/mL) for 10 min. Then, cells were lysed and the 
indicated proteins were detected by Western blotting with or without 
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immunoprecipitation of Aki1.  
Figure 2 
Effects of Aki1 siRNA on cell viability and apoptosis in EGFR mutant human lung cancer 
cell lines. Cells were treated with Aki1-1 or control scramble siRNA. (A) After 72 h 
incubation, cell viability was determined by MTT assay. (B) After 24 h incubation with 
control scramble siRNA (lanes 1, 3, and 5) or Aki1-1 siRNA (lanes 2, 4, 6), cells were 
lysed and the indicated proteins were detected by Western blotting. (C) After 48 h 
incubation, cell apoptosis was determined with an Annexin V-FITC Apoptosis Detection 
Kit I. The numbers show percentages of early apoptotic cells. 
Figure 3 
Comparison of efficacy between Aki1 knockdown and EGFR inhibition on cell viability. 
Cells were treated with Aki1-1 siRNA, EGFR siRNA, control scramble siRNA, or 
erlotinib (1 μM). (A) After 72 h incubation, cell viability was determined by MTT assay. 
(B) After 24 h incubation, cells were lysed and the indicated proteins were detected by 
Western blotting.  
Figure 4 
Therapeutic effects of Aki1 knockdown against lung cancer cells with EGFR T790M 
secondary mutation in vivo. H1975 cells (5×106 cells per 100 μL of PBS) were injected 
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subcutaneously into the flanks of 5-week-old male SCID mice. After cell inoculation, 50 
μg of either scramble or Aki1 siRNA complexed with Invivofectamine was injected 
intratumorally on days 5 and 8. (A) Tumor size was measured twice a week and tumor 
volume was calculated as described in Materials and methods. (B) Macroscopic 
appearance of the tumors harvested on day 26. (C) The harvested tumors were 
examined for Aki1, and the inhibition of downstream signaling molecule, S6, in tumors 
by Western blotting. 
Figure 5 
Effects of Aki1 knockdown combined with new generation EGFR-TKI in lung cancer with 
EGFR T790M secondary mutation. H1975 cells were treated with Aki1-1 or control 
scramble siRNA in the presence or absence of erlotinib (1 μM), CL-387,785 (0.3 μM), 
BIBW2992 (0.1 μM), or WZ4002 (0.1 μM). (A) After 72 h incubation, cell viability was 
determined by MTT assay. *, P < 0.01, one-way ANOVA. (B) After 24 h incubation, cells 
were lysed and the indicated proteins were detected by Western blotting. (C) Schema 
showing the role of Aki1 in cells with wild-type EGFR and mutant EGFR. 
Figure 6 
Aki1 is frequently expressed in EGFR mutant lung cancer. Clinical specimens from 
EGFR mutant lung cancer patients were stained for Aki1 by immunohistochemistry. (A) 
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A total of 56 tumor specimens with EGFR-activating mutations were obtained from 56 
lung adenocarcinoma patients. Of the 56 patients, 42 were EGFR-TKI naïve, 7 tumors 
were from patients who showed intrinsic resistance to the EGFR-TKIs, gefitinib or 
erlotinib. Another 7 tumors were from patients who showed acquired resistance to 
EGFR-TKIs. Of 42 EGFR-TKI naïve tumors, the presence of Aki1 protein was scored as 
2+ in 31 tumors (74%), 1+ in 8 tumors (19%), and – in 3 tumors (7%). Aki1 protein was 
detected diffusely in all of 7 tumors with intrinsic resistance: 2+ in 4 (57%), 1+ in 3 (43%). 
Aki1 protein was detected diffusely in all of 7 tumors with acquired resistance: 2+ in 6 
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